Background The morbidity and mortality of advanced-stage head and neck squamous cell carcinoma (HNSCC) are still high, despite innovative advances in treatment1. Current research strategies pay a growing attention on cold atmospheric pressure plasma (CAP). Objective In this article, selected clinical results in CAP therapy of palliative HNSCC patients are presented. The current state of preclinical and clinical research on plasma medical oncology is summarized, with special regard to immunity aspects. Results A prospective observation study2 investigated the therapeutic effect of CAP treatment in locally advanced HNSCC (UICC IV) patients who failed to response to the standard treatment. In this palliative intended trial one third of the patients showed a remarkable partial tumor remission under CAP therapy. The patients could be confidently identified as a responder or non-responder to CAP treatment within the first two weeks after intervention. In the group of responder patients, the tumor surface decreased by 80% in size compared to the baseline. The effectiveness of CAP got lost after a long plateau phase. Both, the effectivity and the loss of effectivity can be interpreted by new immunological insights. Apart from the active components of plasma (e.g. ROS/RNS), that modify the redox level and the activation level of signaling pathways in cancer and immune cells, the regulation of immunogenic cells is a key component. Conclusion Plasma therapy has the ability to locally effect the immune system and to modify the tumor microenvironment- opening perspectives for improved therapeutic concepts.
Read full abstract